Metoprolol Succinate vs Tartrate: Critical Formulation Selection

Key Clinical Distinctions

The American Heart Association recommends metoprolol succinate for patients with heart failure with reduced ejection fraction, as it has proven mortality reduction, with a 34% reduction in all-cause mortality, 38% reduction in cardiovascular mortality, 41% reduction in sudden death, and 49% reduction in death from progressive heart failure 1, 2, 3
For patients with hypertension without heart failure, the American College of Cardiology suggests that either metoprolol formulation can be used, though succinate offers convenience, with a dosing range of 50-200 mg once daily for metoprolol succinate and 100-200 mg daily in 2 divided doses for metoprolol tartrate 1, 4
The European Society of Cardiology recommends avoiding beta-blockers as first-line agents for hypertension unless the patient has ischemic heart disease or heart failure, and to start metoprolol succinate at 12.5-25 mg once daily and titrate by doubling every 2 weeks to target dose of 200 mg once daily 1, 2, 3

For heart failure with reduced ejection fraction, the American Heart Association recommends prescribing metoprolol succinate only, starting at 12.5-25 mg once daily and titrating to a target dose of 200 mg once daily, with a minimum dose of 100 mg daily if the target dose is not tolerated 2, 3, 5
For hypertension without heart failure, the American College of Cardiology suggests that either formulation can be used, with metoprolol succinate preferred for once-daily convenience, and metoprolol tartrate dosed at 100-200 mg in divided doses 1, 4

For worsening congestion, the European Society of Cardiology recommends first doubling the diuretic dose, then halving the metoprolol dose only if increasing the diuretic fails, and monitoring heart rate, blood pressure, signs of congestion, and symptoms of worsening heart failure 3
For symptomatic hypotension, the American College of Cardiology suggests first reducing or eliminating vasodilators, then reducing the diuretic if no congestion is present, and temporarily reducing the metoprolol dose by 50% 3

During titration, the American Heart Association recommends assessing heart rate, blood pressure, signs of congestion, symptoms of worsening heart failure, and blood chemistry at 12 weeks after initiation and 12 weeks after final dose 3, 5

Only three beta-blockers have proven mortality reduction in heart failure: bisoprolol, carvedilol, and metoprolol succinate—this is not a class effect, according to the American Heart Association 6